Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study

Cytometry B Clin Cytom. 2011 Nov;80(6):346-53. doi: 10.1002/cyto.b.20613. Epub 2011 Oct 4.

Abstract

Background: The development of flow cytometry as a useful tool for the detection of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) is potentially hampered by the fact that a normal subset of B-cells with a similar immunophenotype is present in the peripheral blood. This subset of CLL-like cells is not well defined in terms of frequency.

Methods: Here, we performed a multicenter study with a panel of four-color antibody combinations possibly useful for the detection of MRD in CLL, to establish the levels of normal CLL-like cells in 49 healthy controls. ROC curves established the upper level of such cells at 4 × 10(-4) . The two best combinations were further applied to 419 samples from 117 treated CLL patients.

Results: The combinations CD19/CD5/CD43/CD79b and CD19/CD5/CD81/CD22 appeared very robust and well correlated to enumerate normal CLL-like cells in a lysis no-wash approach. In follow-up samples from CLL patients, they disclosed only 9.8% of the samples within the normal range. In more than 90% of the cases, it was thus possible to report confidently on the absence or presence of MRD in these patients.

Conclusions: This manuscript reports on the frequency of CD19(+) CD5(+) B-cells in normal peripheral blood and confirms the combinations recommended by the European research initiative on CLL as being performing to assess remaining CLL cells above a threshold of 4 × 10(-4) white blood cells.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD19 / blood
  • Antigens, CD19 / immunology
  • B-Lymphocytes / chemistry*
  • CD5 Antigens / blood
  • CD5 Antigens / immunology
  • Cyclophosphamide / therapeutic use
  • Female
  • Flow Cytometry
  • Follow-Up Studies
  • Humans
  • Immunophenotyping / standards*
  • Leukemia, Lymphocytic, Chronic, B-Cell / blood
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Neoplasm, Residual / blood
  • Neoplasm, Residual / diagnosis*
  • Neoplasm, Residual / immunology
  • ROC Curve
  • Reference Values
  • Sensitivity and Specificity
  • Vidarabine / analogs & derivatives
  • Vidarabine / therapeutic use

Substances

  • Antigens, CD19
  • CD5 Antigens
  • Cyclophosphamide
  • Vidarabine
  • fludarabine